Tearsheet

Teladoc Health (TDOC)


Market Price (12/5/2025): $7.75 | Market Cap: $1.4 Bil
Sector: Health Care | Industry: Health Care Technology

Teladoc Health (TDOC)


Market Price (12/5/2025): $7.75
Market Cap: $1.4 Bil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow


0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12%
Weak multi-year price returns
2Y Excs Rtn is -107%, 3Y Excs Rtn is -145%
Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -179 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.1%
1 Attractive yield
FCF Yield is 10%
Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15%
Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.4%, Rev Chg QQuarterly Revenue Change % is -2.2%
2 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more.
  Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%
0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12%
1 Attractive yield
FCF Yield is 10%
2 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -107%, 3Y Excs Rtn is -145%
4 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15%
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -179 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.1%
6 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.4%, Rev Chg QQuarterly Revenue Change % is -2.2%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%

Valuation, Metrics & Events

TDOC Stock


Why The Stock Moved


Qualitative Assessment

AI Generated Analysis | Feedback

Teladoc Health (TDOC) experienced movement in its stock, influenced by various corporate developments and market conditions. While the precise 0.6% movement for a future period cannot be explained, the following key points highlight factors that have recently impacted the stock based on available information up to early December 2024, or for future guidance given in late 2024 for 2025.

1. Mixed Q3 2024 Financial Results: Teladoc Health reported mixed financial results for the third quarter of 2024. The company's consolidated revenue decreased by 3% year-over-year to $640.5 million. However, the Integrated Care segment saw a 2% increase in revenue, while the BetterHelp segment experienced a 10% decline. The net loss per share improved to $0.19, down from a $0.35 loss in Q3 2023, and free cash flow increased by 16% year-over-year to $79 million. This mix of declines in overall revenue and BetterHelp, coupled with growth in Integrated Care and improved net loss, likely contributed to fluctuations in investor sentiment.

2. BetterHelp Segment Underperformance: The BetterHelp segment continued to be a drag on Teladoc's overall performance, with a 10% drop in revenue in Q3 2024 and a significant non-cash goodwill impairment charge of $790 million recorded in the first nine months of 2024, attributed to changes in future cash flow estimates related to this segment. The ongoing challenges and uncertainties surrounding BetterHelp's revenue and future guidance have likely created downward pressure on the stock.

Show more

Stock Movement Drivers

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
TDOC Return139%-54%-74%-9%-58%-14%-91%
Peers Return74%14%-32%8%-16%70%109%
S&P 500 Return16%27%-19%24%23%17%112%

Monthly Win Rates [3]
TDOC Win Rate83%25%25%50%25%40% 
Peers Win Rate28%32%47%55%38%48% 
S&P 500 Win Rate58%75%42%67%75%70% 

Max Drawdowns [4]
TDOC Max Drawdown-1%-56%-75%-34%-68%-28% 
Peers Max Drawdown-14%-6%-52%-19%-39%-21% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: GH, PRVA, LFST, FLGT, INNV. See TDOC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/4/2025 (YTD)

How Low Can It Go

Unique KeyEventTDOCS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-94.7%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven1791.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-30.9%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven44.6%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven73 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-50.3%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven101.4%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven378 days120 days

Compare to GH, PRVA, LFST, FLGT, INNV


In The Past

Teladoc Health's stock fell -94.7% during the 2022 Inflation Shock from a high on 2/8/2021. A -94.7% loss requires a 1791.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Teladoc Health (TDOC)

Better Bets than Teladoc Health (TDOC)

Latest Trefis Analyses

Trade Ideas

Select past ideas related to TDOC. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
10.0%10.0%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-7.7%-7.7%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
6.9%6.9%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
11.5%11.5%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
8.9%8.9%-5.1%
TDOC_4302024_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG04302024TDOCTeladoc HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
-30.0%-43.6%-48.9%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
10.0%10.0%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-7.7%-7.7%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
6.9%6.9%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
11.5%11.5%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
8.9%8.9%-5.1%
TDOC_4302024_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG04302024TDOCTeladoc HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
-30.0%-43.6%-48.9%

Recent Active Movers

Recent Active Movers

More From Trefis

Peer Comparisons for Teladoc Health

Peers to compare with:

Financials

TDOCGHPRVALFSTFLGTINNVMedian
NameTeladoc .Guardant.Privia H.LifeStan.Fulgent .InnovAge  
Mkt Price7.78108.5224.006.4628.305.1515.89
Mkt Cap1.413.52.92.50.90.71.9
Rev LTM2,5289032,0431,3683168851,135
Op Inc LTM-179-442287-71-3-37
FCF LTM140-262111119-203673
FCF 3Y Avg153-3008539-9-915
CFO LTM293-22311115124478
CFO 3Y Avg305-271857219245

Growth & Margins

TDOCGHPRVALFSTFLGTINNVMedian
NameTeladoc .Guardant.Privia H.LifeStan.Fulgent .InnovAge  
Rev Chg LTM-2.4%30.4%19.0%13.4%13.6%12.5%13.5%
Rev Chg 3Y Avg3.0%28.0%17.4%18.6%-17.9%8.4%12.9%
Rev Chg Q-2.2%38.5%32.5%16.3%17.2%15.1%16.8%
QoQ Delta Rev Chg LTM-0.6%8.9%7.5%3.9%4.1%3.6%4.0%
Op Mgn LTM-7.1%-49.0%1.4%0.5%-22.5%-0.3%-3.7%
Op Mgn 3Y Avg-7.6%-73.1%1.2%-8.4%-27.6%-2.9%-8.0%
QoQ Delta Op Mgn LTM0.2%6.6%0.3%0.5%1.5%1.6%1.0%
CFO/Rev LTM11.6%-24.7%5.4%11.0%0.5%5.0%5.2%
CFO/Rev 3Y Avg11.9%-41.4%4.7%5.5%6.7%-0.0%5.1%
FCF/Rev LTM5.5%-29.1%5.4%8.7%-6.3%4.1%4.7%
FCF/Rev 3Y Avg6.0%-45.5%4.7%2.6%-3.0%-1.6%0.5%

Valuation

TDOCGHPRVALFSTFLGTINNVMedian
NameTeladoc .Guardant.Privia H.LifeStan.Fulgent .InnovAge  
Mkt Cap1.413.52.92.50.90.71.9
P/S0.58.61.51.62.20.81.5
P/EBIT-6.0-19.8108.4329.1-12.2-41.8-9.1
P/E-6.1-19.6168.3-233.4-16.2-40.3-17.9
P/CFO4.7-35.027.614.1456.315.814.9
Total Yield-16.3%-5.1%0.6%-0.4%-6.2%-2.5%-3.8%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg9.0%-7.8%3.3%1.8%-1.5%-0.9%0.5%
D/E0.80.20.00.20.00.10.2
Net D/E0.20.1-0.10.1-0.5-0.00.0

Returns

TDOCGHPRVALFSTFLGTINNVMedian
NameTeladoc .Guardant.Privia H.LifeStan.Fulgent .InnovAge  
1M Rtn-2.5%10.6%-2.8%29.7%23.7%6.4%8.5%
3M Rtn2.0%76.9%3.8%18.1%28.8%41.1%23.4%
6M Rtn12.3%124.2%5.3%8.9%35.9%29.7%21.0%
12M Rtn-29.4%184.8%9.1%-11.9%40.1%7.3%8.2%
3Y Rtn-71.3%108.9%2.0%13.9%-21.2%-31.1%-9.6%
1M Excs Rtn-3.8%9.3%-4.1%28.5%22.4%5.1%7.2%
3M Excs Rtn-6.3%74.7%-2.7%14.5%23.1%30.1%18.8%
6M Excs Rtn-3.2%108.7%-10.2%-6.5%20.5%14.3%5.5%
12M Excs Rtn-45.7%192.1%-5.8%-27.4%31.2%-8.3%-7.1%
3Y Excs Rtn-144.6%46.0%-65.6%-33.7%-92.8%-91.0%-78.3%

Financials

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Integrated Care1,4691,3741,301  
BetterHelp1,1341,020721  
Other0131125 
Access Fees Revenue   847463
Visit Fee Revenue   22290
Total2,6022,4072,0331,094553


Operating Income by Segment
$ Mil20242023202220212020
Integrated Care192135   
BetterHelp136114   
Goodwill impairment0-13,403   
Other0-3   
Depreciation of property and equipment-11-11   
Restructuring costs-17-7   
Acquisition, integration, and transformation costs-21-16   
Stock-based compensation-202-218   
Amortization of intangible assets-326-245   
Total-249-13,653   


Price Behavior

Short Interest

Short Interest: As Of Date11142025
Short Interest: Shares Quantity26,417,176
Short Interest: % Change Since 1031202511.7%
Average Daily Volume6,578,598
Days-to-Cover Short Interest4.02
Basic Shares Quantity176,934,781
Short % of Basic Shares14.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
93020251030202510-Q 9/30/2025
6302025730202510-Q 6/30/2025
3312025501202510-Q 3/31/2025
12312024227202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024801202410-Q 6/30/2024
3312024426202410-Q 3/31/2024
12312023223202410-K 12/31/2023
93020231027202310-Q 9/30/2023
6302023728202310-Q 6/30/2023
3312023502202310-Q 3/31/2023
12312022301202310-K 12/31/2022
93020221102202210-Q 9/30/2022
6302022803202210-Q 6/30/2022
3312022502202210-Q 3/31/2022
12312021228202210-K 12/31/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value
Value of
Held Shares
Form
0Paulus Kenneth H 11172025Buy6.9410,00069,40069,400Form